Advertisement

Advertisement

2021 ASH Annual Meeting & Exposition

Leukemia

AGILE Study: Addition of Ivosidenib to Azacitidine Triples Median Overall Survival in Difficult-to-Treat AML Population

In patients with newly diagnosed acute myeloid leukemia (AML) with an IDH1 mutation who were ineligible for intensive chemotherapy, the addition of the IDH1 inhibitor ivosidenib to azacitidine signifi...

multiple myeloma
immunotherapy

Romanos Sklavenitis-Pistofidis, MD, on Smoldering Myeloma: Identifying Biomarkers of Response to Immunotherapy

Romanos Sklavenitis-Pistofidis, MD, of Dana-Farber Cancer Institute, discusses study findings on a next generation of clinical assays to assess both tumor biology and immune state, as well as common c...

multiple myeloma
genomics/genetics

Anil Aktas-Samur, PhD, on Identifying Low-Risk Smoldering Multiple Myeloma

Anil Aktas-Samur, PhD, of Dana-Farber Cancer Institute, discusses study findings on the genomic characterization of non-progressor smoldering multiple myeloma, results that may provide a molecular def...

leukemia
genomics/genetics

Musa Yilmaz, MD, on FLT3-ITD–Mutated AML: Findings on Quizartinib With Decitabine and Venetoclax

Musa Yilmaz, MD, of The University of Texas MD Anderson Cancer Center, discusses study results suggesting that quizartinib with decitabine and venetoclax is active in patients with FLT3-ITD–mutated ac...

lymphoma
immunotherapy

Manali Kamdar, MD, on Large B-Cell Lymphoma: Lisocabtagene Maraleucel vs the Standard of Care

Manali Kamdar, MD, of the University of Colorado Cancer Center, discusses phase III results from the TRANSFORM study, which suggest that lisocabtagene maraleucel, a CD19-directed CAR T-cell therapy, i...

lymphoma
genomics/genetics

Joe Schroers-Martin, MD, on Follicular Lymphoma: Precursor Mutations May Be Detectable Years Before Diagnosis

Joe Schroers-Martin, MD, of Stanford University, discusses his latest study findings, which show that follicular lymphoma driver mutations are detectable in blood and saliva years prior to a clinical ...

multiple myeloma
covid-19

Nikhil C. Munshi, MD, PhD, on COVID-19 Vaccine Effectiveness in Patients With Multiple Myeloma

Nikhil C. Munshi, MD, PhD, of Dana-Farber Cancer Institute, discusses the findings from a large nationwide Veterans Affairs study, which showed that, for patients with multiple myeloma, the effectiven...

leukemia

Sangeetha Venugopal, MD, on Secondary AML: Impact of Front-Line Treatment Approach

Sangeetha Venugopal, MD, of The University of Texas MD Anderson Cancer Center, discusses a retrospective analysis of 562 patients with treated secondary acute myeloid leukemia and prior exposure to hy...

leukemia

Andrew Matthews, MD, on AML: CPX-351 vs Venetoclax/Azacitidine for Initial Therapy

Andrew Matthews, MD, of the Abramson Cancer Center, University of Pennsylvania, discusses findings from a retrospective study at an academic institution, which showed there was no statistically signif...

Multiple Myeloma
Immunotherapy
Genomics/Genetics

Molecular Analysis Advances Risk Profiling and Assessment of Immunotherapy Response in Smoldering Myeloma

Molecular and genetic research has advanced the categorization of different risk groups in patients with smoldering myeloma. Notable presentations at the 2021 American Society of Hematology (ASH) Annu...

Leukemia

Expert Point of View: Krish Patel, MD

Krish Patel, MD, Director of the Lymphoma Program at the Swedish Cancer Institute in Seattle and Interim Director of the Hematological Malignancies and Cellular Therapy Program, commented on the impli...

Leukemia

Measurable Residual Disease Kinetics: A Potential New Tool in CLL

Achieving undetectable measurable residual disease (MRD) is an important milestone in the treatment of patients with chronic lymphocytic leukemia (CLL) as well as those with other hematologic malignan...

leukemia
myelodysplastic syndromes

Alba Rodriguez-Meira, DPhil, on TP53-Mutated Leukemic Transformation in Myeloproliferative Neoplasms

Alba Rodriguez-Meira, DPhil, of the University of Oxford, discusses a comprehensive analysis of the genetic, cellular, and molecular landscape of TP53-mediated transformation, providing insights into ...

hematologic malignancies
supportive care

Leslie S. Kean, MD, PhD, on Bone Marrow Transplantation: Using Abatacept to Prevent Graft-vs-Host Disease

Leslie S. Kean, MD, PhD, of Dana-Farber/Boston Children's Cancer and Blood Disorders Center, discusses findings from her analysis of the International Blood and Marrow Transplant Research Database, wh...

leukemia
genomics/genetics

Eunice S. Wang, MD, on FLT3-Mutated AML: Gilteritinib and Azacitidine for Intensive Induction Chemotherapy–Ineligible Patients

Eunice S. Wang, MD, of Roswell Park Comprehensive Cancer Center, discusses phase III results showing that gilteritinib and azacitidine led to significantly higher composite complete response rates in ...

lymphoma
immunotherapy

Roni Shouval, MD, PhD, on TP53-Mutant Large B-Cell Lymphoma and CAR T-Cell Therapy

Roni Shouval, MD, PhD, of Memorial Sloan Kettering Cancer Center, discusses his findings, which show, for the first time, that TP53 alterations are a valuable prognostic and potentially predictive mar...

lymphoma
immunotherapy

Michael R. Bishop, MD, on Aggressive B-Cell NHL: Tisagenlecleucel vs Standard of Care as Second-Line Therapy

Michael R. Bishop, MD, of the University of Chicago, discusses insights from findings of the phase III BELINDA study, which may inform the design of future CAR T-cell trials, as well as the use of sec...

leukemia

Carsten Utoft Niemann, MD, PhD, on CLL: Time-Limited Venetoclax and Ibrutinib for Patients With Relapsed or Refractory Disease

Carsten Utoft Niemann, MD, PhD, of Copenhagen University Hospital, discusses a primary analysis of the phase II Vision HO141 trial, which showed the feasibility of stopping and restarting ibrutinib an...

leukemia

Masayuki Umeda, MD, on Pediatric AML: Identifying a Key Subtype-Defining Lesion

Masayuki Umeda, MD, of St. Jude Children's Research Hospital, discusses his research which showed that UBTF-TD (upstream binding transcription factor-tandem duplications) define a unique subtype of ac...

Immunotherapy
Supportive Care
Hematologic Malignancies

Study Examines a Potential Approach to Mitigate CAR T-Cell Therapy Toxicity

Research demonstrating a novel approach that may reduce cytokine-release syndrome associated with chimeric antigen receptor (CAR) T-cell therapy was presented by Marcela Maus, MD, PhD, and colleagues ...

Leukemia

Ibrutinib Plus Fludarabine, Cyclophosphamide, and Rituximab for Younger Patients With CLL

A study presented by Matthew S. Davids, MD, of Dana-Farber Cancer Institute, and colleagues at the 2021 American Society of Hematology (ASH) Annual Meeting & Exposition (Abstract 640) suggests tha...

multiple myeloma

Tarek H. Mouhieddine, MD, on Relapsed/Refractory Multiple Myeloma and Bispecific Antibodies

Tarek H. Mouhieddine, MD, of The Mount Sinai Hospital and The Icahn School of Medicine at Mount Sinai, discusses data that suggest patients with heavily pretreated, predominantly triple-class refracto...

leukemia
genomics/genetics

Talha Badar, MD, on TP53-Mutated AML and the Impact of Allogeneic Stem Cell Transplantation on Survival

Talha Badar, MD, of the Mayo Clinic, discusses the near-universal poor outcomes for patients with TP53-mutated acute myeloid leukemia and the findings that show allogeneic stem cell transplantation ap...

Lymphoma

POLARIX: Pola-R-CHP vs R-CHOP for Previously Untreated Patients With DLBCL

The POLARIX study found patients with diffuse large B-cell lymphoma (DLBCL) had a significantly higher likelihood of survival without disease progression 2 years after receiving a new drug combination...

Lymphoma
Immunotherapy

BELINDA Study: Second-Line Tisagenlecleucel Equivalent to Standard of Care for Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma

In an analysis of the phase III BELINDA trial presented by Bishop et al during the 2021 American Society of Hematology (ASH) Annual Meeting & Exposition (Abstract LBA-6), the chimeric antigen rece...

Lymphoma

ZUMA-7 Primary Analysis: Second-Line Axicabtagene Ciloleucel Quadruples Event-Free Survival in Large B-Cell Lymphoma

In the primary analysis of the phase III ZUMA-7 trial, the chimeric antigen receptor (CAR) T-cell therapy axicabtagene ciloleucel led to a fourfold increase in event-free survival over the standard o...

Leukemia
Myelodysplastic Syndromes

Study Identifies Factors for Severe COVID-19 Illness Among Patients With Acute Leukemia or MDS

In separate analyses of 257 patients with acute leukemia or myelodysplastic syndrome (MDS) who developed COVID-19 and are part of the American Society of Hematology (ASH) RC COVID-19 Registry for Hema...

lymphoma

Daniel A. Ermann, MD, on DLBCL: Outcomes With Consolidative Radiation Therapy

Daniel A. Ermann, MD, of the Huntsman Cancer Institute, University of Utah, discusses results from the largest retrospective study on outcomes utilizing radiotherapy in early-stage diffuse large B-cel...

lymphoma
immunotherapy

L. Elizabeth Budde, MD, PhD, on Relapsed/Refractory Follicular Lymphoma: Early Results on Mosunetuzumab Monotherapy

L. Elizabeth Budde, MD, PhD, of City of Hope, discusses phase I/II findings that showed mosunetuzumab monotherapy induces deep and durable remissions in patients with relapsed or refractory follicular...

Multiple Myeloma
Immunotherapy

Isatuximab/RVd Meets Primary Endpoint of MRD Negativity for Newly Diagnosed, Transplant-Eligible Patients With Multiple Myeloma

For the first-line treatment of newly diagnosed, transplant-eligible patients with multiple myeloma, the achievement of measurable residual disease (MRD) negativity was significantly greater when the ...

Leukemia
Palliative Care

Study Reveals Gaps in Code Status Discussions Among Patients With High-Risk AML

Oncologists and health-care professionals who treat patients with high-risk acute myeloid leukemia (AML) are missing important opportunities to have end-of-life discussions at earlier stages in the di...

Hematologic Malignancies
COVID-19

Antibody Response to COVID-19 Vaccination in Patients With Myeloid and Lymphoid Neoplasms

According to a German study by Rotterdam et al presented at the 2021 American Society of Hematology (ASH) Annual Meeting & Exposition (Abstract 218), about 15% of people with blood cancers and oth...

Hematologic Malignancies
COVID-19

ASH RC COVID-19 Registry for Hematology: Risk Factors for Hospitalization and Death Among Patients With Hematologic Malignancies Infected With COVID-19

Patients with blood cancers, particularly those with more advanced disease, are at increased risk for serious COVID-19 outcomes, including an elevated chance of severe illness or death from infection,...

Leukemia
Genomics/Genetics

Ivosidenib/Azacitidine vs Azacitidine Alone in Patients With Newly Diagnosed IDH1-Mutated AML

In the phase III AGILE trial, the combination of ivosidenib and azacitidine was found to be superior in treating newly diagnosed patients with IDH1-mutated acute myeloid leukemia (AML) compared to aza...

Myelodysplastic Syndromes
Leukemia
COVID-19

Antibody Response to Second Dose of mRNA COVID-19 Vaccine in Patients With AML and MDS

In one of the largest studies to date of the antibody response to vaccination against COVID-19 in people who had been treated for acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), patie...

leukemia

Paolo Ghia, MD, PhD, on CLL: New Data on Treatment With Ibrutinib Plus Venetoclax

Paolo Ghia, MD, PhD, of the Università Vita-Salute San Raffaele and IRCCS Ospedale San Raffaele, discusses disease-free survival results from the measurable residual disease cohort of the phase II CAP...

Lymphoma
Immunotherapy

TRANSFORM Trial: Lisocabtagene Maraleucel vs Standard of Care for Relapsed or Refractory Large B-Cell Lymphoma

An interim analysis of the TRANSFORM trial comparing the chimeric antigen receptor (CAR) T-cell immunotherapy lisocabtagene maraleucel to standard of care found that the CAR T-cell therapy significant...

Lymphoma
Immunotherapy

Activity of Mosunetuzumab in Pretreated Patients With Relapsed or Refractory Follicular Lymphoma

The bispecific antibody mosunetuzumab achieved deep and durable remissions as monotherapy in patients with relapsed or refractory follicular lymphoma who had received two or more prior lines of therap...

Leukemia

Study Reveals Underrepresentation of AYA Hispanic Patients in a Large ALL Clinical Trial

A study of U.S. adolescent and young adult patients with acute lymphoblastic leukemia (ALL) found that Hispanic patients were significantly underrepresented in a large clinical trial compared with the...

Leukemia

Outcomes Among Pediatric and Young Adult Patients With ALL Differ By Race, Ethnicity, and Socioeconomic Status

A study of nearly 25,000 patients with acute lymphoblastic leukemia (ALL) aged up to 30 years old revealed significant gaps in survival rates between White, Hispanic, and Black patients, as well as wo...

Advertisement

Advertisement



Advertisement